Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 233-239

  Koto, Kazutaka ^a   Murata, Hiroaki ^a   Kimura, Shinya ^b   Horie, Naoyuki ^a   Matsui, Takaaki ^a   Nishigaki, Yasunori ^a   Ryu, Kazuteru ^a   Sakabe, Tomoya ^a   Itoi, Megumi ^a   Ashihara, Eishi ^c   Maekawa, Taira ^c   Fushiki, Shinji ^a   Kubo, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Bisphosphonates; Cell cycle arrest; Combined effects; Fibrosarcoma; Zoledronic acid

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FIBROSARCOMA; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; SARCOMA CELL; TUMOR GROWTH; WESTERN BLOTTING; CELL CYCLE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FIBROSARCOMA; HUMANS; IMIDAZOLES; TIME FACTORS;

EID: 77952964440     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000851     Document Type: Article

References (40)

1. Pritchard DJ, Sim FH, Ivins JC, Soule EH and Dahlin DC: Fibrosarcoma of bone and soft tissues of the trunk and extremities. Orthop Clin North Am 8: 869-881, 1977. (Pubitemid 8249406)
2. Pritchard DJ, Soule EH, Taylor WF and Ivins JC: Fibrosarcoma, a clinic-pathologic and statistical study of 199 tumors of the soft tissue of the extremities and trunk. Cancer 33: 888-897, 1974.
3. Scott SM, Reiman HM, Pritchard DJ and Ilstrup DM: Soft tissue fibrosarcoma. A clinicopathologic study of 132 cases. Cancer 64: 925-931, 1989.
4. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M and Ikeda Y: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15: 719-727, 2003. (Pubitemid 36556076)
5. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M and Irimajiri K: A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 73: 2655-2664, 2003.
6. Kuroda J, Kimura S, Segawa H, et al: The third-generation bisphosphonate zolendronate synergistically augments the anti-PhC leukemia activity of imatinib mesylate. Blood 102: 2229-2235, 2003. (Pubitemid 37122403)
7. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001. (Pubitemid 32685845)
8. Gouin F, Ory B, Redlini F and Heymann D: Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curettage and increases overall survival. Int J Cancer 119: 980-984, 2006. (Pubitemid 44116903)
9. Kubo T, Shimosae S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A and Ochi M: Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 24: 1138-1144, 2006. (Pubitemid 43870875)
10. Russel RG and Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106, 1999.
11. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA and Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 255: 491-494, 1999.
12. Van Beek E, Pieterman E, Cohen L, Lowwik C and Papapoulos S: Nitrogen-containing bishosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthas activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255: 235-242, 2001. (Pubitemid 29292287)
13. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242, 2001. (Pubitemid 32112446)
14. Benford HL, McGowan NW, Helfrich MH, Nuttall ME and Rogers MJ: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28: 465-473, 2001.
15. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A and Rogers MJ: Protein geranylgeraylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15: 1467-1476, 2000.
16. Anderson KC, Kyle RA, Dalton WSm, Landowski T, Shain K, Jove R, Hazlehurst L and Berenson J: Multiple myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program 1: 147-165, 2000.
17. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Chen B; Zoledoronic acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-reflectory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468, 2000.
18. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D and Seaman JJ: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial, The Zoledronic acid Lung cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150-3157, 2003. (Pubitemid 46606297)
19. Muraro M, Mereuta OM, Carraro F, Madon E and Faggioli F: Osteosarcoma cell line growth inhibition by zoledronate stimulated effector cells. Cell Immunol 249: 63-72, 2007.
20. Boissier S, Magnetto S, Frappart L, Cusin B, Ebetino FH, Delmas PD and Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890-3894, 1997. (Pubitemid 27427670)
21. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas PD, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastasis. Cancer Res 60: 2949-2954, 2000. (Pubitemid 30395820)
22. Horie N, Murata H, Nishigaki Y, Matsui T, Segawa H, Nogawa M, Yuasa T, Kimura S, Maekawa T, Fushiki S and Kubo T: The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett 238: 111-118, 2006. (Pubitemid 43851150)
23. Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T, Watanabe M, Adachi S, Maekawa T, Fushiki S and Kubo T: Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 274: 271-278, 2009.
24. Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T and Fushiki S: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anti-cancer agents against murine osteosarcoma. Br J Cancer 96: 255-261, 2007. (Pubitemid 46160630)
25. Neville-Webbe HL, Evans CA, Coleman RE and Holen I: Mechanisms of the synergistic interaction between the bisphosphonate zoledoronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 27: 92-103, 2006.
26. Jagdev SP, Coleman RE, Shipman CM, Rostami-HA and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001.
27. Kubo T, Shimose S, Matsuo T, Sakai A and Ochi M: Efficacy of a nitrogen-containning bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicine against malignant tumor cells. Cancer Chemother Pharmcol 62: 111-116, 2008. (Pubitemid 351537851)
28. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE and Holen I: Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178, 2008.
29. Ottewel PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P and Holen I: Differential effect of doxorubicin and zoledoronic acid on intraosseus versus extraosseus breast tumor growth in vivo. Clin Cancer Res 14: 4658-4666, 2008.
30. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE and Hole I: Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by Doxorubicin in breast and prostate cancer cells. Int J Cancer 113: 364-371, 2005. (Pubitemid 40038702)
31. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG and Cole SP: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53: 3221-3225, 1993. (Pubitemid 23223284)
32. Slovak ML, Ho J P, Cole SPS, et al: The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16. Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55: 4214-4219, 1995.
33. Reszka AA, Halasy-Nagy J and Rodan GA: Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyto model for esophageal irritation. Mol Pharmacol 59: 193-202, 2001. (Pubitemid 32108550)
34. Turhan AG, Solary E, Vainchenker W and Dusanter-Fourt I: Molecular pathophysiology of chronic myelogeneous leukemia. Hematol Cell Ther 40: 217-221, 1998. (Pubitemid 28500727)
35. Neri A, Knowles DM, Greco A, McCormick F and Dalla-Favera R: Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 85: 9268-9272, 1998.
36. Katz ME and McCormick F: Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 7: 75-79,1997. (Pubitemid 27092767)
37. Matsumoto S, Kimura S, Segawa H, et al: Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31-39, 2005. (Pubitemid 39643239)
38. Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS and Chow KU: In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anticancer Drugs 16: 87-91, 2005.
39. Tassone P, Forciniti S, Galea E, Savino R, Turco MC, Iacopino P, Tagliaferri P, Morrone G, Ciliberto G and Venuta S: Growth inhibition and synergistic induction of apoptosis by zoledronic acidedronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-844, 2000. (Pubitemid 30235061)
40. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG and Maekawa T: Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 79: 37-43, 2004. (Pubitemid 38182199)